Jefferies Initiates Coverage On Damora Therapeutics with Buy Rating, Announces Price Target of $50

Jefferies analyst Akash Tewari initiates coverage on Damora Therapeutics (NASDAQ:DMRA) with a Buy rating and announces Price Target of $50.